StockData
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. (JSPR) stock

JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$13.68+0.31 (+2.32%)

Close on Nov 13, 2026Market cap $455.20MP/E –Yield –

Jasper Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Jasper Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$60.33M. For fiscal 2025 it was -$77.16M. The highest annual figure on record is -$18.27M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$77.16M–
FY2024Dec 31, 2024-$62.60M–
FY2023Dec 31, 2023-$52.07M–
FY2022Dec 31, 2022-$45.86M–
FY2021Dec 31, 2021-$33.68M–
FY2020Dec 31, 2020-$18.27M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.92M–
Q1 FY2026Mar 31, 2026-$14.55M–
Q4 FY2025Dec 31, 2025-$21.87M–
Q3 FY2025Sep 30, 2025-$17.00M–
Q2 FY2025Jun 30, 2025-$15.45M–
Q1 FY2025Mar 31, 2025-$22.84M–
Q4 FY2024Dec 31, 2024-$21.13M–
Q3 FY2024Sep 30, 2024-$14.05M–
Q2 FY2024Jun 30, 2024-$11.68M–
Q1 FY2024Mar 31, 2024-$15.74M–
Q2 FY2023Jun 30, 2023-$13.27M–
Q1 FY2023Mar 31, 2023-$10.34M–
Q4 FY2022Dec 31, 2022-$12.65M–
Q3 FY2022Sep 30, 2022-$9.64M–
Q2 FY2022Jun 30, 2022-$9.36M–
Q1 FY2022Mar 31, 2022-$14.21M–
Q4 FY2021Dec 31, 2021-$14.58M–
Q3 FY2021Sep 30, 2021-$7.11M–
Q2 FY2021Jun 30, 2021-$5.79M–
Q1 FY2021Mar 31, 2021-$6.20M–
Q4 FY2020Dec 31, 2020-$5.39M–
Q3 FY2020Sep 30, 2020-$12.47M–
Q2 FY2020Jun 30, 2020-$173.85K–
Q1 FY2020Mar 31, 2020-$232.87K–

More Jasper Therapeutics figures

See a number that looks wrong?